JankovicV1, Main, Merge, bibRecord, 000D55

The impact of depressive symptoms in early Parkinson disease

Identifieur interne : 000D55 ( Main/Merge ); précédent : 000D54; suivant : 000D56

The impact of depressive symptoms in early Parkinson disease

Auteurs : B Ravina ; R Camicioli ; P Como ; L Marsh ; J Jankovic ; D Weintraub ; J Elm

Source :

Neurology [ 0028-3878 ] ; 2007.

RBID : PMC:2031220

English descriptors

KwdEn :
- Activities of Daily Living, Aged, Antidepressive Agents (therapeutic use), Antiparkinson Agents (adverse effects), Clinical Trials, Phase II as Topic (statistics & numerical data), Cohort Studies, Comorbidity, Depressive Disorder (diagnosis), Depressive Disorder (drug therapy), Depressive Disorder (epidemiology), Disability Evaluation, Double-Blind Method, Early Diagnosis, Female, Humans, Male, Mass Screening, Middle Aged, Motor Activity (drug effects), Motor Activity (physiology), Neuropsychological Tests, Parkinson Disease (drug therapy), Parkinson Disease (epidemiology), Parkinson Disease (physiopathology), Parkinson Disease (psychology), Predictive Value of Tests, Prevalence, Proportional Hazards Models, Randomized Controlled Trials as Topic (statistics & numerical data), Reproducibility of Results.
MESH :
- chemical , adverse effects : Antiparkinson Agents.
- chemical , therapeutic use : Antidepressive Agents.
- diagnosis : Depressive Disorder.
- drug effects : Motor Activity.
- drug therapy : Depressive Disorder, Parkinson Disease.
- epidemiology : Depressive Disorder, Parkinson Disease.
- physiology : Motor Activity.
- physiopathology : Parkinson Disease.
- psychology : Parkinson Disease.
- statistics & numerical data : Clinical Trials, Phase II as Topic, Randomized Controlled Trials as Topic.
- Activities of Daily Living, Aged, Cohort Studies, Comorbidity, Disability Evaluation, Double-Blind Method, Early Diagnosis, Female, Humans, Male, Mass Screening, Middle Aged, Neuropsychological Tests, Predictive Value of Tests, Prevalence, Proportional Hazards Models, Reproducibility of Results.

Abstract

Background

Depressive disorders may affect up to 50% of patients with Parkinson disease (PD) and are associated with increased disability and reduced quality of life. No previous study has systematically examined the impact of depressive symptoms in early, untreated PD.

Methods

We administered the 15-item Geriatric Depression Scale (GDS-15) as part of two NIH-sponsored phase II clinical trials in PD, enrolling 413 early, untreated PD subjects. We used linear mixed models to examine the relationship of depressive symptoms, measured by the GDS-15, with motor function and activities of daily living (ADLs), as measured by the Unified PD Rating Scale (UPDRS). A time-dependent Cox model was used to examine the effect of demographic and clinical outcome measures as predictors of investigator-determined time to need for symptomatic therapy for PD.

Results

A total of 114 (27.6%) subjects screened positive for depression during the average 14.6 months of follow-up. Forty percent of these subjects were neither treated with antidepressants nor referred for further psychiatric evaluation. Depression, as assessed by the GDS-15, was a significant predictor of more impairment in ADLs (p < 0.0001) and increased need for symptomatic therapy of PD (hazard ratio = 1.86; 95% CI 1.29, 2.68).

Conclusions

Clinically important depressive symptoms are common in early Parkinson disease (PD), but are often not treated. Depressive symptoms are an important contributor to disability and the decision to start symptomatic therapy for motor-related impairment in early PD, highlighting the broad importance of identifying and treating depression in this population.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2031220

DOI: 10.1212/01.wnl.0000268695.63392.10
PubMed: 17581943
PubMed Central: 2031220

Links to Exploration step

PMC:2031220

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The impact of depressive symptoms in early Parkinson disease</title>
<author><name sortKey="Ravina, B" sort="Ravina, B" uniqKey="Ravina B" first="B" last="Ravina">B Ravina</name>
</author>
<author><name sortKey="Camicioli, R" sort="Camicioli, R" uniqKey="Camicioli R" first="R" last="Camicioli">R Camicioli</name>
</author>
<author><name sortKey="Como, P G" sort="Como, P G" uniqKey="Como P" first="P" last="Como">P Como</name>
</author>
<author><name sortKey="Marsh, L" sort="Marsh, L" uniqKey="Marsh L" first="L" last="Marsh">L Marsh</name>
</author>
<author><name sortKey="Jankovic, J" sort="Jankovic, J" uniqKey="Jankovic J" first="J" last="Jankovic">J Jankovic</name>
</author>
<author><name sortKey="Weintraub, D" sort="Weintraub, D" uniqKey="Weintraub D" first="D" last="Weintraub">D Weintraub</name>
</author>
<author><name sortKey="Elm, J" sort="Elm, J" uniqKey="Elm J" first="J" last="Elm">J Elm</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">17581943</idno>
<idno type="pmc">2031220</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2031220</idno>
<idno type="RBID">PMC:2031220</idno>
<idno type="doi">10.1212/01.wnl.0000268695.63392.10</idno>
<date when="2007">2007</date>
<idno type="wicri:Area/Pmc/Corpus">000240</idno>
<idno type="wicri:Area/Pmc/Curation">000240</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000239</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="wicri:Area/PubMed/Corpus">000158</idno>
<idno type="wicri:Area/PubMed/Curation">000158</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000153</idno>
<idno type="wicri:Area/Ncbi/Merge">000149</idno>
<idno type="wicri:Area/Ncbi/Curation">000149</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000149</idno>
<idno type="wicri:doubleKey">0028-3878:2007:Ravina B:the:impact:of</idno>
<idno type="wicri:Area/Main/Merge">000D55</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">The impact of depressive symptoms in early Parkinson disease</title>
<author><name sortKey="Ravina, B" sort="Ravina, B" uniqKey="Ravina B" first="B" last="Ravina">B Ravina</name>
</author>
<author><name sortKey="Camicioli, R" sort="Camicioli, R" uniqKey="Camicioli R" first="R" last="Camicioli">R Camicioli</name>
</author>
<author><name sortKey="Como, P G" sort="Como, P G" uniqKey="Como P" first="P" last="Como">P Como</name>
</author>
<author><name sortKey="Marsh, L" sort="Marsh, L" uniqKey="Marsh L" first="L" last="Marsh">L Marsh</name>
</author>
<author><name sortKey="Jankovic, J" sort="Jankovic, J" uniqKey="Jankovic J" first="J" last="Jankovic">J Jankovic</name>
</author>
<author><name sortKey="Weintraub, D" sort="Weintraub, D" uniqKey="Weintraub D" first="D" last="Weintraub">D Weintraub</name>
</author>
<author><name sortKey="Elm, J" sort="Elm, J" uniqKey="Elm J" first="J" last="Elm">J Elm</name>
</author>
</analytic>
<series><title level="j">Neurology</title>
<idno type="ISSN">0028-3878</idno>
<idno type="e-ISSN">1526-632X</idno>
<imprint><date when="2007">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Activities of Daily Living</term>
<term>Aged</term>
<term>Antidepressive Agents (therapeutic use)</term>
<term>Antiparkinson Agents (adverse effects)</term>
<term>Clinical Trials, Phase II as Topic (statistics & numerical data)</term>
<term>Cohort Studies</term>
<term>Comorbidity</term>
<term>Depressive Disorder (diagnosis)</term>
<term>Depressive Disorder (drug therapy)</term>
<term>Depressive Disorder (epidemiology)</term>
<term>Disability Evaluation</term>
<term>Double-Blind Method</term>
<term>Early Diagnosis</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Mass Screening</term>
<term>Middle Aged</term>
<term>Motor Activity (drug effects)</term>
<term>Motor Activity (physiology)</term>
<term>Neuropsychological Tests</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (epidemiology)</term>
<term>Parkinson Disease (physiopathology)</term>
<term>Parkinson Disease (psychology)</term>
<term>Predictive Value of Tests</term>
<term>Prevalence</term>
<term>Proportional Hazards Models</term>
<term>Randomized Controlled Trials as Topic (statistics & numerical data)</term>
<term>Reproducibility of Results</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antidepressive Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Depressive Disorder</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Motor Activity</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Depressive Disorder</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Depressive Disorder</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Motor Activity</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Clinical Trials, Phase II as Topic</term>
<term>Randomized Controlled Trials as Topic</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Activities of Daily Living</term>
<term>Aged</term>
<term>Cohort Studies</term>
<term>Comorbidity</term>
<term>Disability Evaluation</term>
<term>Double-Blind Method</term>
<term>Early Diagnosis</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Mass Screening</term>
<term>Middle Aged</term>
<term>Neuropsychological Tests</term>
<term>Predictive Value of Tests</term>
<term>Prevalence</term>
<term>Proportional Hazards Models</term>
<term>Reproducibility of Results</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><sec id="S1"><title>Background</title>
<p id="P1">Depressive disorders may affect up to 50% of patients with Parkinson disease (PD) and are associated with increased disability and reduced quality of life. No previous study has systematically examined the impact of depressive symptoms in early, untreated PD.</p>
</sec>
<sec sec-type="methods" id="S2"><title>Methods</title>
<p id="P2">We administered the 15-item Geriatric Depression Scale (GDS-15) as part of two NIH-sponsored phase II clinical trials in PD, enrolling 413 early, untreated PD subjects. We used linear mixed models to examine the relationship of depressive symptoms, measured by the GDS-15, with motor function and activities of daily living (ADLs), as measured by the Unified PD Rating Scale (UPDRS). A time-dependent Cox model was used to examine the effect of demographic and clinical outcome measures as predictors of investigator-determined time to need for symptomatic therapy for PD.</p>
</sec>
<sec id="S3"><title>Results</title>
<p id="P3">A total of 114 (27.6%) subjects screened positive for depression during the average 14.6 months of follow-up. Forty percent of these subjects were neither treated with antidepressants nor referred for further psychiatric evaluation. Depression, as assessed by the GDS-15, was a significant predictor of more impairment in ADLs (<italic>p</italic>
 < 0.0001) and increased need for symptomatic therapy of PD (hazard ratio = 1.86; 95% CI 1.29, 2.68).</p>
</sec>
<sec id="S4"><title>Conclusions</title>
<p id="P4">Clinically important depressive symptoms are common in early Parkinson disease (PD), but are often not treated. Depressive symptoms are an important contributor to disability and the decision to start symptomatic therapy for motor-related impairment in early PD, highlighting the broad importance of identifying and treating depression in this population.</p>
</sec>
</div>
</front>
</TEI>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/JankovicV1/Data/Main/Merge

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D55 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 000D55 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    JankovicV1
   |flux=    Main
   |étape=   Merge
   |type=    RBID
   |clé=     PMC:2031220
   |texte=   The impact of depressive symptoms in early Parkinson disease
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Merge/RBID.i   -Sk "pubmed:17581943" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Merge/biblio.hfd   \
       | NlmPubMed2Wicri -a JankovicV1

This area was generated with Dilib version V0.6.19.
Data generation: Wed Feb 10 22:03:07 2016. Site generation: Tue Feb 13 16:14:27 2024

Serveur d'exploration autour de Joseph Jankovic

The impact of depressive symptoms in early Parkinson disease

The impact of depressive symptoms in early Parkinson disease

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Serveur d'exploration autour de Joseph Jankovic
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.